| Program/Indication | Target | Discovery/Lead Optimization | IND Enabling | Phase 1/2 |
|---|---|---|---|---|
| AOC 1001 Myotonic Dystrophy Type 1 (DM1) | DMPK | |||
| AOC 1020 Facioscapulohumeral Muscular Dystrophy (FSHD) | DUX4 | Clinical trial initiations planned for 2022 | ||
| AOC 1044 Duchenne Muscular Dystrophy (DMD) | Exon 44 Dystrophin | Clinical trial initiations planned for 2022 | ||
| Next AOC DMD Programs | Exon 51 Dystrophin | |||
| Exon 45 Dystrophin | ||||
| AOC Muscle Atrophy Muscle Atrophy* | MuRF1 | |||
| AOC Pompe Disease Pompe Disease | GYS1 | |||
| Program/Indication | Target | Stage |
|---|---|---|
| AOC 1001 Myotonic Dystrophy Type 1 (DM1) | DMPK | Phase 1/2 |
| AOC 1020 Facioscapulohumeral Muscular Dystrophy (FSHD) | DUX4 | IND Enabling |
| AOC 1044 Duchenne Muscular Dystrophy (DMD) | Exon 44 Dystrophin | IND Enabling |
| Next AOC DMD Programs | Exon 51 Dystrophin | Discovery/Lead Optimization |
| Exon 45 Dystrophin | Discovery/Lead Optimization | |
| AOC Muscle Atrophy Muscle Atrophy* | MuRF1 | Discovery/Lead Optimization |
| AOC Pompe Disease Pompe Disease | GYS1 | Discovery/Lead Optimization |
* Opportunity for a rare disease indication